Haleos Labs declares ₹1.50 dividend, approves FY26 results, director resignation
Haleos Labs approved audited standalone and consolidated financial results for FY26 ending March 31, 2026. A dividend of ₹1.50 per share was recommended. Mrs. Sundaramma Patibandla resigned as Independent Director. Mrs. Sudeepthi Gopineedi was reappointed as Whole-time Director for five years.
The approval of financial results, dividend recommendation, and changes in directorship (resignation and reappointment) are material events for shareholders and stakeholders, warranting a medium impact.
The announcement contains a mix of routine financial reporting, dividend declaration, director resignation, and director reappointment, which are standard corporate governance events. While the dividend is positive, the resignation is a neutral event. The financial results themselves are presented without significant positive or negative commentary within the announcement.
Haleos Labs Limited announced the outcome of its 97th Board Meeting held on May 29, 2026. The Board approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
The company recommended a dividend of ₹1.50 (15%) per equity share for the financial year 2025-26, subject to shareholder approval at the upcoming 20th Annual General Meeting (AGM). The specific dates for the AGM, book closure, and record date will be announced later.
In terms of corporate actions, the Board accepted the resignation of Mrs. Sundaramma Patibandla as an Independent Director, effective May 29, 2026. Consequently, the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee were reconstituted.
Furthermore, Mrs. Sudeepthi Gopineedi was reappointed as Whole-time Director for a period of five years from September 2, 2026, pending shareholder approval. The Board also approved overall managerial remuneration for Executive Directors, subject to shareholder consent.
Shareholder approval will also be sought via postal ballot for the reappointment of Mrs. Sudeepthi Gopineedi, managerial remuneration, and material related party transactions for the financial year 2026-27 for both the company and its material subsidiary.
The Board approved the appointment of M/s. Suryanarayana & Suresh as statutory auditors for a term of five years and the reappointment of M/s Annapragada & Co. as cost auditors for the financial year 2026-27, both subject to shareholder approval at the AGM.
The company also confirmed that the statutory auditors issued an audit report with an unmodified opinion on the standalone and consolidated financial statements. Related party transactions for the half-year ended March 31, 2026, were also approved.
Details of Key Managerial Personnel authorized for disclosures were provided, including contact information for the Managing Director, Chief Financial Officer, and Company Secretary. The Board meeting commenced at 2:45 pm and concluded at 3:45 pm.
What to do with a filing like this
HALEOS LABS LIMITED filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by HALEOS LABS LIMITED. Read the original for the full detail.